Cantargia ABCHIX:CANTAS 37 Pretax Margin % is -6,490.16% as of Mar. 2026. GuruFocus rates CHIX:CANTAS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Cantargia AB ranks better than 95.45% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Cantargia AB's Pre-Tax Income for the
three
months ended in Mar. 2026 was kr-33.0 Mil. Cantargia AB's Revenue for the
three
months ended in Mar. 2026 was kr0.5 Mil. Therefore, Cantargia AB's pretax margin for the quarter that ended in Mar. 2026 was -6,490.16%.
The historical rank and industry rank for Cantargia AB's Pretax Margin % or its related term are showing as below:
CHIX:CANTAs'
s Pretax Margin % Range Over the Past 10 Years
Min: 46.41 Med: 46.41 Max: 50.73
Current: 50.73
CHIX:CANTAs's Pretax Margin % is ranked better than 95.45% of 945
companies
in the Biotechnology industry
Industry Median: -90.63
vs CHIX:CANTAs: 50.73
Cantargia AB (CHIX:CANTAs) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Cantargia AB Pretax Margin % Related Terms
Cantargia AB Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Cantargia AB's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Cantargia AB's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Cantargia AB's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (CHIX:CANTAS) has a Pretax Margin % of -6,490.16% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cantargia AB and its competitors. Over the past decade, Cantargia AB's Pretax Margin % has ranged from 46.41 to 50.73. According to the industry distribution chart, Cantargia AB ranks #43 out of 945 companies in the Biotechnology industry, placing it in the top 4.6%.
Is Cantargia AB's Pretax Margin % too high?
Cantargia AB's current Pretax Margin % is -6,490.16%. Over the past 10 years, this metric has ranged from a low of 46.41 to a high of 50.73. Based on the distribution chart, Cantargia AB ranks #43 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Cantargia AB has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #43 out of 945 companies for Pretax Margin %. This places Cantargia AB in the top 5% of its industry — outperforming the majority of peers. Historically, Cantargia AB's own Pretax Margin % has ranged from 46.41 to 50.73 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cantargia AB and its competitors. Cantargia AB's current Pretax Margin % is -6,490.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current Pretax Margin % of -6,490.16%. The current Pretax Margin % is -6,490.16%. Cantargia AB's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current Pretax Margin % is -6,490.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
37GF Score
Get the complete analysis for CHIX:CANTAS
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
